Events

Videos

Podcasts

Articles

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Two doses of nivolumab given about 1 month prior to surgery are well tolerated and reduces tumor size in about half of patients with squamous cell carcinoma of the head and neck.

Neoadjuvant Nivolumab Reduces Tumor Size Regardless of HPV Status in Head and Neck Cancer

Nab-paclitaxel (Abraxane) monotherapy has efficacy in patients with pretreated advanced nonsquamous non-small cell lung cancer that is not improved by the addition of CC-486.

Nab-Paclitaxel Alone and With Durvalumab Shows Promise in NSCLC

A liquid biopsy that measures tumor mutational burden showed promise as an aid for predicting benefit in patients with non-small cell lung cancer treated with a checkpoint inhibitor.

Liquid Biopsy for Mutation Burden Predicts PFS in NSCLC Immunotherapy

Emerging Approaches in Liver Cancer

Biomarkers in Liver Cancer

Immunotherapy in Liver Cancer

Ongoing Clinical Trials in Second-Line HCC

Second-Line HCC: Unmet Needs

HCC: Evolution of Frontline Treatment 

Frontline Lenvatinib in HCC: Study 304

Unmet Needs in Systemic Therapy for Liver Cancer

Initial Treatment Decisions in Liver Cancer

Evidence With SIRT in HCC

Role of TACE in Liver Cancer

Radiofrequency Ablation Vs Resection in HCC

HCC and Liver Transplantation

Liver Cancer Screening Strategies

Comorbidities and Management of HCC

Importance of Multidisciplinary Care in Liver Cancer

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer, discusses PD-L1 as a biomarker in lung cancer.

Dr. Gandara Discusses PD-L1 as a Biomarker in Lung Cancer

Immuno-Oncology

Immuno-Oncology | Specialty